Kathryn E Stephenson
Overview
Explore the profile of Kathryn E Stephenson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
62
Citations
3592
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chawana T, Walsh S, Stranix-Chibanda L, Chirenje Z, Yu C, Zhang L, et al.
BMC Immunol
. 2025 Feb;
26(1):8.
PMID: 39966732
VRC07-523LS is a safe and well-tolerated monoclonal antibody (mAb) targeting the CD4 binding site on the HIV envelope (Env) trimer. Efficacy of VRC07-523LS, in combination with mAbs targeting other HIV...
2.
Edupuganti S, Hurt C, Stephenson K, Huang Y, Paez C, Yu C, et al.
Lancet HIV
. 2024 Dec;
12(1):e13-e25.
PMID: 39667379
Background: Multiple broadly neutralising monoclonal antibodies (mAbs) are in development for HIV-1 prevention. The aim of this trial was to test the PGT121.414.LS and VRC07-523LS mAbs for safety and pharmacokinetics...
3.
Banga J, Brock-Fisher T, Petros B, Dai E, Leonelli A, Dobbins S, et al.
Open Forum Infect Dis
. 2024 Nov;
11(11):ofae591.
PMID: 39529936
Background: Households are a major setting for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections, but there remains a lack of knowledge regarding the dynamics of viral transmission, particularly in...
4.
Vanshylla K, Tolboom J, Stephenson K, Feddes-de Boer K, Verwilligen A, Rosendahl Huber S, et al.
NPJ Vaccines
. 2024 Sep;
9(1):179.
PMID: 39349488
The failure of human vaccine efficacy trials assessing a mosaic HIV-1 vaccine calls into question the translatability of preclinical SHIV challenge studies that demonstrated high efficacy of this vaccine in...
5.
Govindan R, Stephenson K
Vaccines (Basel)
. 2024 Sep;
12(9).
PMID: 39340073
Despite rigorous scientific efforts over the forty years since the onset of the global HIV pandemic, a safe and effective HIV-1 vaccine remains elusive. The challenges of HIV vaccine development...
6.
Julg B, Walker-Sperling V, Wagh K, Aid M, Stephenson K, Zash R, et al.
Nat Med
. 2024 Sep;
30(12):3534-3543.
PMID: 39266747
Human immunodeficiency virus type 1 (HIV-1)-specific broadly neutralizing monoclonal antibodies (bNAbs) have to date shown transient viral suppression when administered as monotherapy or as a cocktail of two antibodies. A...
7.
Vielot N, Kelly N, Ludema C, Rosenberg M, Brown E, Janes H, et al.
Vaccine
. 2024 Aug;
42(23):126237.
PMID: 39182315
Background: The introduction of vaccines during the COVID-19 pandemic provided an opportunity to slow transmission of SARS-CoV-2, but initial uptake of COVID-19 vaccination was slow. We analyzed data from a...
8.
Julg B, Stephenson K, Tomaka F, Walsh S, Tan C, Lavreys L, et al.
NPJ Vaccines
. 2024 May;
9(1):89.
PMID: 38782902
Mosaic HIV-1 vaccines have been shown to elicit robust humoral and cellular immune responses in people living with HIV-1 (PLWH), that had started antiretroviral therapy (ART) during acute infection. We...
9.
Cassidy T, Stephenson K, Barouch D, Perelson A
PLoS Comput Biol
. 2024 Mar;
20(3):e1011518.
PMID: 38551976
PGT121 is a broadly neutralizing antibody in clinical development for the treatment and prevention of HIV-1 infection via passive administration. PGT121 targets the HIV-1 V3-glycan and demonstrated potent antiviral activity...
10.
Banga J, Brock-Fisher T, Petros B, Dai E, Leonelli A, Dobbins S, et al.
medRxiv
. 2024 Feb;
PMID: 38370621
Background: Households are a major setting for SARS-CoV-2 infections, but there remains a lack of knowledge regarding the dynamics of viral transmission, particularly in the setting of widespread pre-existing SARS-CoV-2...